Aims: This retrospective, longitudinal study characterised 2430 adults (mean age 40.8 ± 16.1 years) with newly diagnosed type 1 diabetes (T1D) over the first 5 years of insulin treatment. Methods: Data from 1 year pre-and up to 5 years post-insulin initiation were extracted from the UK Clinical Practice Research Datalink (1990-2013). Baseline HbA 1c , BMI and Charlson comorbidity index (CCI) score were compared with data at 1, 2, 3 and 5 years. Results: Mean HbA 1c decreased significantly from baseline 95 ± 32.8 mmol/mol (10.8 ± 3.0%) to 61 ± 21.9 mmol/mol (7.7 ± 2.0%) at 1 year, remaining significantly lower at 2, 3 and 5 years (p < 0.0001). One year after initiating insulin, only 6.3% of patients had HbA 1c <48 mmol/mol (<6.5%). There was no further improvement in HbA1c after 1 year. Mean BMI increased significantly from baseline 25.3 ± 5.5 kg/m 2 to 27.2 ± 5.8 kg/m 2 at 1 year; p < 0.0001), remaining significantly higher thereafter, with over two-thirds having overweight/obesity by year 5. Mean CCI score increased significantly (1.32, baseline; 1.46, year 1; 1.75, year 5). CCI patterns were similar within BMI and HbA 1c strata. Conclusions: More intensive support to reach and maintain glycaemic targets soon postdiagnosis, while avoiding weight gain, and prevention and optimal management of comorbidities are warranted.